Reviewing Scholar Rock (NASDAQ:SRRK) and Oric Pharmaceuticals (NASDAQ:ORIC)

Scholar Rock (NASDAQ:SRRK) and Oric Pharmaceuticals (NASDAQ:ORIC) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.

Risk & Volatility

Scholar Rock has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Oric Pharmaceuticals has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.

Valuation and Earnings

This table compares Scholar Rock and Oric Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94 million	($3.59)	-13.18
Oric Pharmaceuticals	N/A	N/A	-$129.47 million	($1.44)	-5.90

Scholar Rock is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Scholar Rock and Oric Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1	0	12	4	3.12
Oric Pharmaceuticals	1	2	14	0	2.76

Scholar Rock currently has a consensus price target of $56.00, indicating a potential upside of 18.32%. Oric Pharmaceuticals has a consensus price target of $18.92, indicating a potential upside of 122.81%. Given Oric Pharmaceuticals’ higher probable upside, analysts clearly believe Oric Pharmaceuticals is more favorable than Scholar Rock.

Profitability

This table compares Scholar Rock and Oric Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Oric Pharmaceuticals	N/A	-35.33%	-33.31%

Insider & Institutional Ownership

91.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 13.3% of Scholar Rock shares are owned by company insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Oric Pharmaceuticals beats Scholar Rock on 9 of the 12 factors compared between the two stocks.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.